98%
921
2 minutes
20
To overcome the problem of incorrect levodopa (LD) dosage in the treatment of Parkinson's disease, a new analytical tool is urgently needed for accurately determining the concentration of LD in human fluids. Herein, an effective and stable sensor based on a Co-single-atomic-site catalyst (Co-SASC)-modified glassy carbon electrode (Co-SASC/GCE) was developed for the determination of LD concentration. The physicochemical characterization of Co-SASC is systematically investigated. It has excellent thermal stability, graphitization degree, and a large specific surface area. Benefiting from its porous structure for kinetically fast catalysis and component advantages for fix a single cobalt atom to improve stability, Co-SASC/GCE exhibits a superior electrochemical response. Under optimal conditions (pH 2.0, coating amount is 10 μg), an ideal linear relationship is achieved between the logarithm of the peak current of the sensor and the logarithm of LD concentration. The linear range is 0.1-200 μM, and the limit of detection (LOD) is 0.033 μM. After a simple pretreatment, LD in human serum is detected by Co-SASC/GCE with excellent stability and selectivity. As such, this work enlarges the existing electrochemical sensor toolbox by offering a reasonable design and synthesis protocol for advanced materials to accurately determine LD in human fluids for the clinical treatment of Parkinson's disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.talanta.2020.122042 | DOI Listing |
Mov Disord Clin Pract
September 2025
Department of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.
Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).
Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.
Crit Rev Anal Chem
September 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Neurodegenerative disorders (NDD) i.e., dementia of the Alzheimer's type, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are a rising worldwide epidemic driven by aging populations and characterized by progressive neuronal impairment.
View Article and Find Full Text PDFBr J Nurs
September 2025
Senior Director Medical and Clinical Affairs, Convatec Technology Centre, Deeside, UK.
Background: The Neria™ Guard infusion set is indicated for the infusion of several medications for Parkinson's and pain-management therapy.
Aim: The aim of this study was to explore the impact of the Neria Guard infusion set on patients and health professionals from the perspective of nurses.
Method: Two surveys were distributed to nurses: one targeting nurses who use Neria Guard for Parkinson's patients, and one for those who use it for palliative care patients.
Nan Fang Yi Ke Da Xue Xue Bao
August 2025
School of Sports Medicine, Wuhan Sports University, Wuhan 430079, China.
Objectives: To investigate the effects of formulated granules of (TGY) on motor deficits in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced subacute Parkinson's disease (PD) and explore the possible molecular mechanisms.
Methods: Ninety C57BL/6 mice were randomized equally into 6 groups, including a control group, a PD model group, a NEC-1 (6.5 mg/kg) treatment group, two TGY treatment groups at 5 and 2.
Qual Life Res
September 2025
Department of Physical Therapy, Rady Faculty of Health Sciences, College of Rehabilitation Sciences, University of Manitoba, Winnipeg, MB, Canada.
Purpose: The purpose was to identify how the ICECAP-A and ICECAP-O have been used with adults who have neurological health conditions.
Methods: Following the Joanna Briggs Institute framework, a scoping review was conducted, searching five databases (Scopus, CINAHL, MEDLINE, Embase, and PsycINFO). Studies were included if participants were adults (age 18+ years) with neurological health conditions, and ICECAP-A or ICECAP-O were used in the study.